Member Directory
Longer form - Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.. . Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
Appleyard Lees is a leading intellectual property law firm with over sixty patent and trade mark attorneys and litigators.
Who we are and what we do – but also, how we do it – makes us distinctive.
We help our clients protect and monetise their intellectual property, and manage post-grant challenges, should they arise.
We offer broad sector and industry knowledge, plus the ability to adapt our services to specific client requirements, in an agile way.
With offices in UK innovation hotspots, we are positioned to give clients expert strategic IP advice in the UK and worldwide.
Aqdot is a specialist chemical company with a focus and expertise in intelligent encapsulation technology. . . Aqdot’s proprietary technology and know-how enables valuable active products to be protected, delivered and programmed to release where and when required. This unique and disruptive platform technology has the potential to be game-changing in a wide range of industries, including household products, fragrances, personal care, agrochemicals, composites / resin curing and pharmaceuticals. . . Identifying unmet needs in these sectors, we develop products that enable our customers to introduce novel and differentiated products, reduce manufacturing costs, and make a truly positive impact on the environment.
Arecor is the world leader at improving the durability of biologic medicines. Using a rational approach to formulation design, Arecor has generated proprietary technology for stabilising therapeutic proteins, antibodies and vaccines. Arecor has partnered with the world’s largest pharmaceutical companies to enable previously impossible delivery and use options for biologics. As an example of how effective these technologies are – in over 90 per cent of the cases – Arecor’s technology can enable: solid-to-liquid re-formulations; removal of cold-chain; high-concentration delivery, e.g. 200+ mg/ml; and co-formulation of incompatible components.
Arise is an Innovation Hub for businesses specialising in the Health, Performance and Wellbeing sectors, and is part of Anglia Ruskin University (ARU). With Hubs strategically located in Chelmsford and Harlow, occupants can enjoy tailored business support, including access to grant funding, networking opportunities and serviced office facilities.
Arise is supported by the expertise and resources of ARU, providing skills, talent, innovation and business support. Arise is a partnership between ARU and Essex County Council with support from Chelmsford City Council and Harlow Council. This partnership aims to promote business growth in Essex.
Artios - Experts in DDR. We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells
Please watch our video about our open innovation program here https://www.youtube.com/watch?v=rWPkQAae-Cc
Industrial Biotechnology Company using its proprietary technology to make chemicals from sustainable sources.
Astex is dedicated to the discovery and development of novel small molecule therapeutics with a primary focus on oncology. The Company, which is a recognised leader in the field of Fragment Based Drug Discovery, is developing a proprietary pipeline of novel therapies and has a number of other programmes partnered with major pharmaceutical companies with products in clinical development. . . In October 2013, Astex was acquired by Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan. . . For more information about Astex please visit http://www.astx.com